406 related articles for article (PubMed ID: 15834463)
1. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
Gupta R; Kumar G; Kumar RS
Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
[TBL] [Abstract][Full Text] [Related]
2. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
3. Targeting cancer with phosphodiesterase inhibitors.
Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
[TBL] [Abstract][Full Text] [Related]
4. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
Lugnier C
Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family.
Gibson LC; Hastings SF; McPhee I; Clayton RA; Darroch CE; Mackenzie A; Mackenzie FL; Nagasawa M; Stevens PA; Mackenzie SJ
Eur J Pharmacol; 2006 May; 538(1-3):39-42. PubMed ID: 16674936
[TBL] [Abstract][Full Text] [Related]
6. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterases in the central nervous system.
Kleppisch T
Handb Exp Pharmacol; 2009; (191):71-92. PubMed ID: 19089326
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
Kyoi T; Oka M; Noda K; Ukai Y
Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular genetics of the phosphodiesterases (PDEs).
Azevedo MF; Faucz FR; Bimpaki E; Horvath A; Levy I; de Alexandre RB; Ahmad F; Manganiello V; Stratakis CA
Endocr Rev; 2014 Apr; 35(2):195-233. PubMed ID: 24311737
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Castro A; Jerez MJ; Gil C; Martinez A
Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
[TBL] [Abstract][Full Text] [Related]
12. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
13. Cyclic nucleotide phosphodiesterases.
Essayan DM
J Allergy Clin Immunol; 2001 Nov; 108(5):671-80. PubMed ID: 11692087
[TBL] [Abstract][Full Text] [Related]
14. Real-time monitoring of phosphodiesterase inhibition in intact cells.
Herget S; Lohse MJ; Nikolaev VO
Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
[TBL] [Abstract][Full Text] [Related]
15. Cyclic nucleotide-dependent phosphodiesterases (PDEI) inhibition by muscarinic antagonists in bovine tracheal smooth muscle.
Guerra de González L; González de Alfonzo R; Lippo de Bécemberg I; Alfonzo MJ
Biochem Pharmacol; 2004 Aug; 68(4):651-8. PubMed ID: 15276072
[TBL] [Abstract][Full Text] [Related]
16. Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase.
Weiss B
Adv Cyclic Nucleotide Res; 1975; 5():195-211. PubMed ID: 165666
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
Andersson KE; Uckert S; Stief C; Hedlund P
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
[TBL] [Abstract][Full Text] [Related]
18. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
19. Antisense inhibition of phosphodiesterase expression.
Epstein PM
Methods; 1998 Jan; 14(1):21-33. PubMed ID: 9500855
[TBL] [Abstract][Full Text] [Related]
20. [Cyclic nucleotides phosphodiesterases inhibitors].
Hagiwara M; Hidaka H
Nihon Rinsho; 1991 Sep; 49(9):1993-8. PubMed ID: 1660084
[No Abstract] [Full Text] [Related]
[Next] [New Search]
